Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia
复制标题
同种异体干细胞移植治疗B细胞慢性淋巴细胞白血病的疗效
DOI：
--
复制
发表时间：
2000
影响因子：
4.8
通讯作者：
M. Bishop
中科院分区：
文献类型：
--
作者：
Ž. Pavletić;E. Arrowsmith;P. Bierman;S. Goodman;J. Vose;S. Tarantolo;R. Stein;G. Bociek;J. Greer;Cd Wu;J. Kollath;D. Weisenburger;A. Kessinger;S. Wolff;J. Armitage;M. Bishop
本研究的目的是描述一系列 B 细胞慢性淋巴细胞白血病 (B-CLL) 患者的同种异体干细胞移植 (alloSCT) 的结果。 1988 年至 1997 年间，23 名 B-CLL 患者接受了来自相关（n = 20）或无关供体（n = 3）干细胞的移植。患者的中位年龄为 46 岁，之前接受的化疗方案中位数量为两种。移植时，14 名患者患有化疗难治性疾病，其中 12 名患者对氟达拉滨耐药。 23 例中有 22 例的准备方案包括全身照射 (TBI)。所有患者均接受环孢素和甲氨蝶呤预防移植物抗宿主病（GVHD）。 20 名患者 (87%) 达到完全缓解 (CR)。 II-IV级急性GVHD的发生率为54%。 14 名 (61%) 患者存活且无病，其中两名患者捐献者无关，中位生存期为 26 个月（范围为 9-115 个月）。 9 名患者 (39%) 死亡，其中一名患有进展性 B-CLL。 alloSCT 后无失败生存 (FFS) 和总生存 (OS) 的唯一有利预后因素是使用环磷酰胺/TBI，而不是依托泊苷/环磷酰胺/TBI 方案 (P = 0.03)。 alloSCT 后预计的 5 年 FFS、OS 和复发率分别为 65%（95% CI，48-88%）、62%（95% CI，43-88%）和 5%（95%，CI 0-13%）。这些发现证明了高剂量治疗和 alloSCT 在诱导和维持晚期或化学难治性 B-CLL 患者缓解方面的潜力。低复发率可能是由于同种异体移植物抗白血病效应。骨髓移植 (2000) 25, 717–722。
The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II–IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9–115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/ cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48–88%), 62% (95% CI, 43–88%), and 5% (95%, CI 0–13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect. Bone Marrow Transplantation (2000) 25, 717–722.
使用 DNA 限制性片段长度多态性记录骨髓移植后的骨髓植入和混合造血嵌合。
影响因子：
6.2
作者：
Yam,PY;Petz,LD;Knowlton,RG;Wallace,RB;Stock,AD;deLange,G;Brown,VA;Donis-Keller,H;Blume,KG
通讯作者：
Blume,KG
自体和同种异体骨髓移植治疗预后不良的 B 细胞慢性淋巴细胞白血病患者。
影响因子：
20.3
作者：
Rabinowe,SN;Soiffer,RJ;Gribben,JG;Daley,H;Freedman,AS;Daley,J;Pesek,K;Neuberg,D;Pinkus,G;Leavitt,PR
通讯作者：
Leavitt,PR